Journey Medical Corp (DERM)
Healthcare
Drug Manufacturers - Specialty & Generic
6.40 $
-1.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Journey Medical Corp (DERM)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 69.2% of the shares are freely tradable; institutional investors hold 55.8%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
55.8%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
32.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
69.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
23.2%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
22Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Wasatch Advisors LP | 7.75 | 2,133,370 | +62.1 | 03/31/2026 |
| TANG CAPITAL MANAGEMENT LLC | 5.85 | 1,610,000 | -13.2 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.93 | 1,082,080 | +0.0 | 03/31/2026 |
| BlackRock Inc | 3.53 | 972,862 | +35.2 | 03/31/2026 |
| Opaleye Management Inc | 3.49 | 960,000 | -1.5 | 03/31/2026 |
| Vanguard Group Inc | 2.78 | 764,147 | +24.2 | 12/31/2025 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Wasatch Micro Cap | 2.97 | 818,685 | +0.0 | 03/31/2026 |
| Vanguard Total Stock Mkt Idx Inv | 2.86 | 787,989 | -5.6 | 04/30/2026 |
| Wasatch Micro Cap Value Composite | 2.62 | 720,377 | +0.0 | 03/31/2026 |
| Wasatch Micro Cap Value | 2.62 | 720,377 | -0.9 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.